Ancient war paint in fight against breast cancerAugust 14, 2006A plant that gave ancient Britons and Celts their blue war paint, has been found to be a rich source of the anti-cancer compound, glucobrassicin, traditionally associated with broccoli. Glucobrassicin has been found to be effective against breast cancer. The war paint, a blue dye, is obtained from Woad, a member of the Brassicaceae family. Stefania Galletti and her team at the University of Bologna, Italy, found that the plant contains twenty times more cancer fighting chemical glucobrassicin than its relative, broccoli, which they enhanced to nearly 65 times using various treatments (Journal of the Science of Agriculture DOI: 10.1002/jsfa.2571).This compound plays a defensive role in plants, and the researchers found that wounding the leaves can increase levels by 30%. When leaves are damaged, for example, by insects, glucobrassicin is released as a defence mechanism. Its derivatives can kill some plant pests, and also appear to have anti-tumoral properties, and are particularly effective against breast cancer. Glucobrassicin has shown an active role in flushing out cancer-causing chemicals including derivatives of estrogen. Women with higher levels of this hormone are at an increased risk of developing breast cancer. There have been many reports on the health benefits of broccoli and other commonly consumed vegetables from the same family. However, it has been difficult to extract enough of the broccoli compound to carry out extensive tests. Galletti's team hope that by using this cheap, rich source, in depth research can be carried out to study how this compound acts in the body. Society of Chemical Industry |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||